IT service behemoth UST Global to make a substantial investment in Singapore’s MyDoc
Category: #world  By Pankaj Singh  Date: 2017-09-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

IT service behemoth UST Global to make a substantial investment in Singapore’s MyDoc

UST Global, the renowned American multinational provider of digital technology, IT services and solutions, has lately been eyeing the healthcare market prospects across the Asia Pacific and Europe regions with an aim to provide advanced digital healthcare services. In accordance with the same, the company has apparently been planning to invest a certain undisclosed amount in the Singapore-based digital healthcare services discovery platform, MyDoc Pte Ltd. For the record, UST Global provides digital services and advanced compounding to public and private enterprises in about 21 countries across the world.

The newly established MyDoc platform has been conceived with the aim of encouraging the adoption of digital healthcare programs, since digital platforms permit users to conveniently compare, select, and book appointments with hospitals, diagnostic centers, and specialists. This Singapore-based firm apparently provides similar health related services through the web and mobile applications, making it quite popular among the local populace.

UST Global’s investment in MyDoc is anticipated to prove rather beneficial for the latter, as it would help the company enhance its digital health program related to health data tracking and disease management. One of UST Global’s top shots has been quoted stating that the company’s investment in MyDoc is likely to add substantial value to the firm’s business model, thereby contributing to the expansion of its consumer pool. In addition, experts cite that this investment is a major step with regards to digital transformation in healthcare industry.

MyDoc’s digital platform is inclusive of several players in healthcare sector, through which users would be able to gain access to long-term healthcare management programs and myriad other healthcare services such as online prescriptions and doctor consultations. In addition, a digital portfolio allows users to access their health insurance details as well. MyDoc has a fairly wide range of clients – it includes renowned insurers such as Aetna, AXA, and AIA, government partners such as the Health Promotion Board of Singapore, and providers such as the Guardian Pharmacy.

UST Global’s dominant technological capabilities in the healthcare sector are certain to favor the Singapore based digital healthcare service company to develop next generation facilities in the future. Apart from the financial support, the partnership with UST Global is predicted to help MyDoc to accomplish its mission of developing Smart Nation initiatives in Singapore.

Singapore based start-up company, MyDoc is likely to gain a stronger hold in Asia Pacific, owing to the vast customer base and expertise in digital technology of its partner UST Global. Moreover, the modern skillsets of UST Global in cloud computing, artificial intelligence, and Human Centric Design will undeniably help MyDoc to improve product portfolio over the years ahead.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...